NDI draft guidance

Algae Health Sciences gets NDI for high dose astaxanthin

Algae Health Sciences gets NDI for high dose astaxanthin

By Stephen Daniells

The US Food and Drug Administration has accepted a New Dietary Ingredient (NDI) notification from Algae Health Sciences, Inc., a subsidiary of BGG, for high-dose but limited duration astaxanthin dosing.

Vinpocetine is derived from vincamine obtained from the lesser periwinkle plant (Vinca minor L.). Image © Ryan Kaldari

Linnea requests FDA to withdrawal vinpocetine notice

By Stephen Daniells

Ingredient supplier Linnea has added its voice to the vinpocetine issue, submitting comments requesting the FDA to withdraw the tentative conclusion that vinpocetine cannot be used as a dietary ingredient.

© iStock / Jezperklauzen

13 things we learned from the IPA’s DC Workshop

By Stephen Daniells

From market sizing to the positions from FDA and FTC on NDIs and claims substantiation, the International Probiotic Association’s DC workshop succeeded in providing a venue for sharing knowledge and expertise.

Lesser Periwinkle Plant (Vinca minor). Image © Ryan Kaldari

Senator Hatch urges withdrawal of vinpocetine notice

By Stephen Daniells

Dietary supplement champion Sen Orrin Hatch (R-UT) is calling for the withdrawal of a Federal Register Notice that questioned the regulatory status of vinpocetine as a new dietary ingredient.

© iStock / studioportosabbia

Ten things to change about DSHEA

By Stephen Daniells

If you could change one thing about the Dietary Supplements Health & Education Act, what would it be? Ten industry lawyers weighed in…

FDA extends NDI comment period to Dec. 12

FDA extends NDI comment period to Dec. 12

By Hank Schultz

The Food and Drug Administration has extended the comment period on the updated draft version of the New Dietary Ingredients guidance. The new deadline for comments is Dec. 12.

Follow us

Featured Events

View more

Products

View more

Webinars